Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SAR448851 in early Alzheimer's disease
CTR20263599Phase 2Active
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SAR448851 in Alzheimer's disease (AD), sponsored by Sanofi. Started Oct 2026; status: active.
02
Drugs
SAR448851
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20263599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263599.